NewAmsterdamPharma
Last verified 2026-06-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $453.0Mattributed |
|---|---|
| Latest round | seed, $453.0M, 2024-12-01attributed |
| Founded | 2019 |
| Headquarters | Amsterdam |
| Industry | bio |
| Stage | series-b+ |
| Website | newamsterdampharma.com |
NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor for cardiovascular disease in patients who cannot reach LDL targets on statins alone. Patients with familial hypercholesterolemia and atherosclerotic disease are the target population. The company spun out the program from Amgen and is pursuing Phase 3 clinical readouts.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-12-01 | seed | $453.0M | undisclosed |
Detected tech stack
adobe fonts, cloudflare, cloudflare bot management, google tag manager, http/3, jquery 3.7.1, mysql, php, typekit, wordpress, wp engine, yoast seo 27.7
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $453.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $453.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | newamsterdampharma.com, read 2026-06-05 |
| Description | self-reported | newamsterdampharma.com, read 2026-06-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.